Compare Medpace Holdings Inc (MEDP) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Walmart Stores Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Walmart Stores Inc trades at $111.35 (market cap $877.15B). The key difference: Walmart Stores Inc is far larger — about 52.1× Medpace Holdings Inc's market cap, and Walmart Stores Inc pays a 0.9% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Walmart Stores Inc for 101 Days on average.
| MEDP | WMT | |
|---|---|---|
Market Cap | $16.82B | $877.15B |
Volume | 223,093 | 23,616,578 |
Sector | Health | Consumer Staples |
52-Week High | $630.19 | $134.20 |
52-Week Low | $393.42 | $100.61 |
Typical Hold Time | 14 Days | 101 Days |
Enterprise Value | $16.44B | $939.38B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Walmart (WMT) trades at $108.11, up 0.82% today, with a neutral technical signal and strong fundamentals. Revenue grew to $681.0B in 2025, with net income rising to $19.4B and a 2.85% margin. The company has beaten EPS estimates for three consecutive quarters, and analyst consensus is a Buy with a $128.84 price target. Recent news highlights expansion in AI, e-commerce, and Medicare Advantage plans, supporting market share gains.
The outlook is positive due to consistent earnings beats, digital growth, and strategic initiatives, but risks include high valuation (P/E 40.06), rising costs, and economic sensitivity. Upside potential exists toward the consensus target, though near-term volatility may persist amid inflation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
